Amyotrophic Lateral Sclerosis (ALS) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026
- Published Date : July 27, 2026
- Updated On : September 23, 2026
- Pages : 53
Amyotrophic Lateral Sclerosis Emerging Therapy and TPP Insights
Thelansis’s “Amyotrophic Lateral Sclerosis (ALS) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Amyotrophic Lateral Sclerosis Overview
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the degeneration of upper and lower motor neurons in the brain and spinal cord, leading to loss of voluntary muscle control. Clinical manifestations vary but commonly include asymmetric limb weakness, muscle atrophy, fasciculations, spasticity, impaired speech and swallowing, and progressive respiratory dysfunction. ALS may occur sporadically or in association with inherited genetic variants, with disease biology involving multiple interacting mechanisms such as excitotoxicity, protein misfolding, mitochondrial dysfunction, impaired RNA processing, axonal transport abnormalities, and neuroinflammation. Disease progression is highly variable, but increasing motor impairment can ultimately result in respiratory failure and substantial loss of independence. Management requires multidisciplinary care addressing nutrition, communication, mobility, respiratory function, and symptom burden, alongside therapies intended to slow disease progression. Despite advances in genetic and molecular understanding, effective treatments remain limited, creating continued interest in antisense oligonucleotides, RNA-targeted approaches, neuroprotective agents, and other mechanism-driven therapies aimed at preserving motor-neuron function and extending meaningful survival.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by surveys* with physician / key opinion leaders:
- Survey findings are corroborated and enriched by insights from interviews with leading KOLs
*Survey is customized based on client requirements
Deliverables format:
- PowerPoint presentation
- MS Excel
Key business questions answered:
- Detailed emerging competitive landscape
- Pipeline analysis
- Target patients for emerging therapies
- Key companies
- Key mechanism of actions
- Launch date estimates, etc.
- Clinical trial landscape analysis
- Target patient segments
- Trial endpoints
- Trial design
- Recruitment criteria, etc.
- Unmet Needs and Opportunities
- Performance of key current therapies
- Top areas of unmet needs
- Opportunity sizing for key unmet needs
- Target Product Profiles
- Attributes and levels
- Physician likelihood of prescribing
- Expected patient shares
- KOL insights on key emerging therapies
- Level of awareness
- Expected use / line of therapy
- Extent to fulfil key unmet needs
- KOL quotes
Amyotrophic Lateral Sclerosis Emerging Therapy and TPP Insights
Thelansis’s “Amyotrophic Lateral Sclerosis (ALS) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Amyotrophic Lateral Sclerosis Overview
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the degeneration of upper and lower motor neurons in the brain and spinal cord, leading to loss of voluntary muscle control. Clinical manifestations vary but commonly include asymmetric limb weakness, muscle atrophy, fasciculations, spasticity, impaired speech and swallowing, and progressive respiratory dysfunction. ALS may occur sporadically or in association with inherited genetic variants, with disease biology involving multiple interacting mechanisms such as excitotoxicity, protein misfolding, mitochondrial dysfunction, impaired RNA processing, axonal transport abnormalities, and neuroinflammation. Disease progression is highly variable, but increasing motor impairment can ultimately result in respiratory failure and substantial loss of independence. Management requires multidisciplinary care addressing nutrition, communication, mobility, respiratory function, and symptom burden, alongside therapies intended to slow disease progression. Despite advances in genetic and molecular understanding, effective treatments remain limited, creating continued interest in antisense oligonucleotides, RNA-targeted approaches, neuroprotective agents, and other mechanism-driven therapies aimed at preserving motor-neuron function and extending meaningful survival.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by surveys* with physician / key opinion leaders:
- Survey findings are corroborated and enriched by insights from interviews with leading KOLs
*Survey is customized based on client requirements
Deliverables format:
- PowerPoint presentation
- MS Excel
Key business questions answered:
- Detailed emerging competitive landscape
- Pipeline analysis
- Target patients for emerging therapies
- Key companies
- Key mechanism of actions
- Launch date estimates, etc.
- Clinical trial landscape analysis
- Target patient segments
- Trial endpoints
- Trial design
- Recruitment criteria, etc.
- Unmet Needs and Opportunities
- Performance of key current therapies
- Top areas of unmet needs
- Opportunity sizing for key unmet needs
- Target Product Profiles
- Attributes and levels
- Physician likelihood of prescribing
- Expected patient shares
- KOL insights on key emerging therapies
- Level of awareness
- Expected use / line of therapy
- Extent to fulfil key unmet needs
- KOL quotes
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.
2. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key emerging therapies – profiles and KOL insights
3. Product Attribute Analysis
- Key takeaways
- Scientific attributes
- Commercial attributes
- Product positioning
4. Primary Market Research
- Current treatment landscape
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Current challenges
- Unmet needs
- Emerging therapies
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Unmet needs and KOL expectations
5. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.
2. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key emerging therapies – profiles and KOL insights
3. Product Attribute Analysis
- Key takeaways
- Scientific attributes
- Commercial attributes
- Product positioning
4. Primary Market Research
- Current treatment landscape
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Current challenges
- Unmet needs
- Emerging therapies
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Unmet needs and KOL expectations
5. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
